The US government has secured 100 million doses of Moderna’s mRNA vaccine against COVID-19.
The government has paid Moderna, the Cambridge, UK-based biotech pioneering mRNA therapeutics and vaccines, up to $1.525 billion for the doses of mRNA-1273. This includes incentive payments for timely delivery of the product.
With the previous award of up to $955 million from BARDA for the development of mRNA-1273 to licensure, this latest investment brings the US government commitments for early access to mRNA-1273 to up to $2.48 billion.
The government, as a part of Operation Warp Speed, will also have the option to purchase up to an additional 400 million doses of mRNA-1273 from Moderna.
“We appreciate the confidence of the U.S. government in our mRNA vaccine platform and the continued support,” said Moderna CEO, Stéphane Bancel.
“We are advancing the clinical development of mRNA-1273 with the ongoing Phase 3 study being conducted in collaboration with NIAID and BARDA.
“In parallel, we are scaling up our manufacturing capability with our strategic partners, Lonza, Catalent and Rovi, to address this global health emergency with a safe and effective vaccine.”
HHS Secretary Alex Azar said: “For Operation Warp Speed, we are assembling a broad portfolio of vaccines to increase the odds that we will have at least one safe, effective vaccine as soon as the end of this year.
“With this latest investment, we will have supported the vaccine candidate developed by Moderna in partnership with the NIH all the way from early development through clinical trials and now manufacturing, with the potential to bring millions of safe and effective doses to the American people.”